How a unique DES platform translates into clinical differentiation with MiStent: from premise to proven effectiveness

Sponsored by Micell Technologies

Chairperson: P.W. Serruys

Learning Objectives

  • To know the science behind controlled elution and crystalline sirolimus
  • To hear and discuss late-breaking trial data from DESSOLVE III
  • To preview the MiStent OCT substudy and discuss the daily use of MiStent